Evidence map›Paper›PMID 40777665›Full record

ArticleFrontiers in nephrology2025

Case Report: Fruquintinib-induced hyperbilirubinemia: a rare cause of dialyzer filter discoloration in a patient undergoing long-term dialysis.

Mercedes Galloway, Alaa S Awad, Charles W Heilig

Abstract readCase Reports
In one paragraph

Article in Frontiers in nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mercedes GallowayNephrology, University of Florida, Jacksonville, FL, United States.
Alaa S AwadNephrology, University of Florida, Jacksonville, FL, United States.
Charles W HeiligNephrology, University of Florida, Jacksonville, FL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of a 55-year-old male patient with a medical history of cardiorenal syndrome and rectosigmoid colon adenocarcinoma, who started dialysis five years prior to presenting with unusual yellow discoloration of his dialyzer filter during his regular dialysis session. Following a regimen of standard chemotherapy, the patient was initiated on fruquintinib, 5 mg daily for 21 days, as an alternative treatment due to the intolerability of previous agents and failure of malignancy to respond. Shortly after starting fruquintinib, the patient developed hyperbilirubinemia and experienced significant yellow discoloration of the dialysis filter-a phenomenon not previously documented in association with this medication. The absence of dialyzer discoloration during five years of dialysis highlights the temporal relationship between the introduction of fruquintinib and the onset of filter discoloration. [removed some sentence] This case highlights the need for heightened awareness of potential adverse effects of fruquintinib, potentially detectable in patients undergoing dialysis, and aims to contribute to the growing body of literature on the medication's safety profile.

Indexed as

dialysisESRDfilter discolorationfruquintinibhyperbilirubinemiaVEGF pathway

Identifiers

PMID40777665
PMCPMC12328136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.